Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05065840 · ClinicalTrials.gov registry record · NA
Advancing HPV Vaccination Among HIV Positive Adults: The CHAMPS Study
A NA study of Human Papilloma Virus and Human Papilloma Virus Vaccine, sponsored by Emory University.
- Recruiting
- Registry status
- NA
- Development phase
- 365
- Enrollment target
- 4
- Study locations
NCT05065840: Recruiting NA study of Human Papilloma Virus and Human Papilloma Virus Vaccine, sponsored by Emory University.
NCT05065840 is a NA study of Human Papilloma Virus and Human Papilloma Virus Vaccine that is actively recruiting participants, run by Emory University. The registered enrollment target is 365 participants, below the 8,432-participant average among 39 other Human Papilloma Virus trials with a reported enrollment target (96% lower). The trial reports 4 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05065840, a NA study of Human Papilloma Virus and Human Papilloma Virus Vaccine, is actively recruiting participants, sponsored by Emory University.
- RECRUITING
- Registry status
- NA
- Development phase
- 365 participants
- Enrollment target
- 4
- Study locations
Study Summary
People living with HIV (PLWH) are 28 times more likely to be diagnosed with Human Papillomavirus (HPV) - associated anal cancer than the general population. The HPV vaccine is an effective and safe approach to prevent and reduce the risk of HPV-related disease among PLWH. HPV vaccine programs tailored and implemented in the HIV population are lagging for this high-risk group. The CDC's 4 Pillars Transformation Program is a multi-level, evidence-based intervention that has been successfully used to increase HPV vaccination in the general population and is ready to be tested in the high-risk HIV population, particularly PLWH in the rural South. This program offers providers and clinic staff evidence-based strategies to increase HPV vaccination uptake via training and educational resources. This study proposes to tailor and refine the 4 Pillars Program and conduct this project in three HIV clinics in Georgia.
Primary Outcome
Initiation of the HPV vaccine is defined as receiving the first or second immunization from the series. This variable will be measured by electronic medical records and GRITS at 24 months post baseline.
Conditions Studied
Interventions
- BEHAVIORAL CDC 4 Pillars Program
Study Locations (4)
Georgia
- Albany Rural Model Clinic - Albany
- AID Atlanta - Atlanta
- Faebris - Atlanta
- AHF Lithonia - Lithonia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 365 participants |
| Start Date | 2023-05-22 |
| Est. Completion | 2027-06-01 |
| Phase | NA |
What NCT05065840 shows while recruiting
NCT05065840 is an interventional study that assigns participants to a tested intervention. The registered 365 participants enrollment target is mid-sized for trials with a published cap, below the 8,432-participant average among 39 other Human Papilloma Virus trials with a reported enrollment target (96% lower).
The record links to 2 conditions, with Human Papilloma Virus appearing as the primary indexed condition, and to 1 intervention - of which CDC 4 Pillars Program is the first listed.
NCT05065840 reports a single indexed study location in Georgia.
Frequently Asked Questions
What is clinical trial NCT05065840 about?
NCT05065840 is a clinical study titled "Advancing HPV Vaccination Among HIV Positive Adults: The CHAMPS Study". People living with HIV (PLWH) are 28 times more likely to be diagnosed with Human Papillomavirus (HPV) - associated anal cancer than the general population. The HPV vaccine is an effective and safe approach to prevent and reduce the risk of HPV-related disease among PLWH. HPV vaccine programs tailor...
What is the current status of trial NCT05065840?
This trial is currently recruiting. It is a NA study. The enrollment target is 365 participants. The study started on 2023-05-22. Estimated completion is 2027-06-01.
What conditions does trial NCT05065840 study?
This clinical trial studies the following conditions: Human Papilloma Virus, Human Papilloma Virus Vaccine.
What interventions are being tested in trial NCT05065840?
The interventions under investigation include: CDC 4 Pillars Program (BEHAVIORAL).
Who is sponsoring clinical trial NCT05065840?
This trial is sponsored by Emory University, which has 1,208 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05065840 being conducted?
This trial has 4 study locations across Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Human Papilloma Virus
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05065840's enrollment target sits among peer trials
365 16th of 39 higher than 24 of 39 other Human Papilloma Virus trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Human Papilloma Virus trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Educate and Improve Underserved Populations' Uptake and Completion of the HPV Vaccine
RECRUITING · NA
-
PopSci CHW4CervixHealth
RECRUITING · NA
-
Provider Recommendation and HPV Vaccination
RECRUITING · NA
-
Impact of Standing Orders Optimization
ACTIVE NOT RECRUITING · NA
-
Development of a Self-collection Device for Cervical Cancer Screening
ACTIVE NOT RECRUITING · NA
-
Impact of Financial Incentives
ACTIVE NOT RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04049604 · 365 participants · NA
IDENTIFY Study: Natural History of Maternal Neoplasia
- NCT05303519 · 365 participants · Phase 3
SIGMA (Safusidenib in IDH1 Mutant Glioma Maintenance)
- NCT05592626 · 365 participants · Phase 1
A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors
- NCT05669430 · 365 participants · Phase 1
A Study of GV20-0251 Monotherapy and GV20-0251 in Combination With Pembrolizumab in Participants With Solid Tumor Malignancies
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI